AbbVie Conference: Year-End HS Readouts, SubQ SKYRIZI Data and New IBD Combo Roadmap in Focus

AbbVie Conference: Year-End HS Readouts, SubQ SKYRIZI Data and New IBD Combo Roadmap in Focus

Executives from AbbVie (NYSE:ABBV) outlined upcoming clinical milestones and development priorities across hidradenitis suppurativa (HS), inflammatory bowel disease (IBD), and several earlier-stage immunology programs during a recent discussion focused on differentiation, combination strategies, and next-generation platforms. HS: IL-1 bispecific lutikizumab and RINVOQ readouts expected by year-end Company leaders emphasized that HS remains a sig…